■HER2阳性与HER2阴性胃癌之间的TMB比较 HER2阳性患者,HER2阴性患者和具有ARID1A突变的HER2阴性患者的中位TMB值分别为14.6,16.2和17.7(图6A,Mann-Whitney U试验,HER2阳性vs HER2阴性p=0.15,HER2阳性vs 具有ARID1A突变的HER2阴性p=0.22)。具有ARID1A突变的HER2阳性患...
■HER2阳性与HER2阴性胃癌之间的TMB比较 HER2阳性患者,HER2阴性患者和具有ARID1A突变的HER2阴性患者的中位TMB值分别为14.6,16.2和17.7(图6A,Mann-Whitney U试验,HER2阳性vs HER2阴性p=0.15,HER2阳性vs 具有ARID1A突变的HER2阴性p=0.22)。具有ARID1A突变的HER2阳性患者的中位TMB值为16.2。在HER2阴性胃癌患者中,特别是...
相反,在2022年圣安东尼奥乳腺癌研讨会(SABCS)上,德国乳腺组(GBG)提出了新的发现,表明相对于恒定HER2低表达组,从HER2零表达变为HER2低表达与无侵袭性DFS(iDFS)降低显著相关(恒定HER2低表达vs HER2零表达至低表达,HR 1.43;95%CI,1.01–2.01;p=0.04)[7]。而在本研究中发现在HR阳性患者中,HER2零表达到低表达的...
研究团队对7例TNBC患者(HER2-negative vs HER2-low,4 vs 3)的36168个细胞进行单细胞RNA测序(scRNA-seq),以进一步探索两种不同表型的TNBC之间肿瘤生物学特性的差异。结果显示: 与HER2-low TNBC相比,HER2-negativeative TNBC内皮细胞(1.8%对8...
HER2阳性患者,HER2阴性患者和具有ARID1A突变的HER2阴性患者的中位TMB值分别为14.6,16.2和17.7 muts/Mb(图6A,Mann-Whitney U试验,HER2阳性vs HER2阴性p = 0.15,HER2阳性vs具有ARID1A突变的HER2阴性p = 0.22)。具有ARID1A突变的HER2阳性患者的中位TMB值为16.2。在HER2阴性胃癌患者中,特别是在ARID1A突变患者中,TMB...
[5] Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733. [6] Howlader N, Cronin KA, Kurian AW et al (2018) Differences in breast cancer survival by molecular subtypes in...
[2].Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113.[3].Rugo HS, Rumble RB, Macrae E, ...
[18] Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2...
研究团队对7例TNBC患者(HER2-negative vs HER2-low,4 vs 3)的36168个细胞进行单细胞RNA测序(scRNA-seq),以进一步探索两种不同表型的TNBC之间肿瘤生物学特性的差异。结果显示: 与HER2-low TNBC相比,HER2-negativeative TNBC内皮细胞(1.8%对8.1%,P < 0.05)和成纤维细胞(1.8%对8.1%,P < 0.05)占比较...
2. Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113. ...